Journal of the Endocrine Society最新文献

{"title":"Cardiometabolic Improvements After Metabolic Surgery and Related Presurgery Factors.","authors":"Lei Wang, Michael T O'Brien, Xinmeng Zhang, You Chen, Wayne J English, Brandon Williams, Matthew Spann, Vance Albaugh, Xiao-Ou Shu, Charles R Flynn, Danxia Yu","doi":"10.1210/jendso/bvae027","DOIUrl":"10.1210/jendso/bvae027","url":null,"abstract":"<p><strong>Context: </strong>Metabolic surgery remains the most effective and durable treatment for severe obesity and related metabolic diseases.</p><p><strong>Objective: </strong>We examined cardiometabolic improvements after metabolic surgery and associated presurgery demographic and clinical factors in a large multiracial cohort.</p><p><strong>Methods: </strong>Included were 7804 patients (20-79 years) undergoing first-time metabolic surgery at Vanderbilt University Medical Center from 1999 to 2022. Pre- and 1-year postsurgery cardiometabolic profiles were extracted from medical records, including body mass index (BMI), blood pressure, blood lipids, glucose, and hemoglobin A1c. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk was estimated per American College of Cardiology/American Heart Association equations. Pre- to postsurgery cardiometabolic profiles were compared by paired t-test, and associated factors were identified by multivariable linear and logistic regression.</p><p><strong>Results: </strong>Among 7804 patients, most were women and White, while 1618 were men and 1271 were Black; median age and BMI were 45 years [interquartile range (IQR): 37-53] and 46.4 kg/m² (IQR: 42.1-52.4). At 1-year postsurgery, patients showed significant decreases in systolic blood pressure (10.5 [95% confidence interval: 10.1, 10.9] mmHg), total cholesterol (13.5 [10.3, 16.7] mg/dL), glucose (13.6 [12.9, 14.4] mg/dL), hemoglobin A1c (1.13% [1.06, 1.20]), and 10-year ASCVD risk (absolute reduction: 1.58% [1.22, 1.94]; relative reduction: 34.4% [29.4, 39.3]); all <i>P</i> < .0001. Older, male, or Black patients showed less reduction in 10-year ASCVD risk and lower odds of diabetes/hypertension/dyslipidemia remission than younger, female, or White patients. Patients with a history of diabetes, hypertension, dyslipidemia, or cardiovascular disease showed less cardiometabolic improvements than those without. Results were similar with or without further adjusting for weight loss and largely sustained at 2-year postsurgery.</p><p><strong>Conclusion: </strong>Metabolic surgery results in significant cardiometabolic improvements, particularly among younger, female, or White patients and those without comorbidities.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae027"},"PeriodicalIF":4.1,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recognition of Reviewers.","authors":"","doi":"10.1210/jendso/bvae011","DOIUrl":"https://doi.org/10.1210/jendso/bvae011","url":null,"abstract":"","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 4","pages":"bvae011"},"PeriodicalIF":4.1,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long Covid: Hormone Imbalances and/or Rather Complex Immune Dysregulations?","authors":"Christian A Koch","doi":"10.1210/jendso/bvae043","DOIUrl":"10.1210/jendso/bvae043","url":null,"abstract":"","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae043"},"PeriodicalIF":4.1,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight Loss Outcomes in a Veterans Affairs Pharmacotherapy-based Weight Management Clinic.","authors":"Kevin Ni, Elisa Rogowitz, Abtin K Farahmand, Laura K Kaizer, Jaron Arbet, Christina R Cunningham, Elizabeth A Thomas, David R Saxon","doi":"10.1210/jendso/bvae042","DOIUrl":"10.1210/jendso/bvae042","url":null,"abstract":"<p><strong>Context: </strong>Despite a high prevalence of obesity in the veteran population, antiobesity medications (AOMs) have been underused in the Veterans Health Administration. Real-world reports on outcomes when AOMs have been used in veterans is limited.</p><p><strong>Objective: </strong>To analyze weight loss outcomes from a local Veterans Health Administration pharmacotherapy-based weight management clinic (WMC).</p><p><strong>Methods: </strong>This was a retrospective cohort study of veterans enrolled in a local WMC for 15 months from August 2016 through September 2018 and followed through November 2019. Patients were offered 1 of 5 available AOMs based on their comorbidities. Factors associated with weight loss (5% or more weight loss) were assessed.</p><p><strong>Key results: </strong>A total of 159 patients were seen in a WMC, 149 (93.7%) veterans were prescribed an AOM, and 129 returned for follow-up. Overall, 61/129 (47%) patients achieved 5% or greater weight loss and 28/129 (22%) achieved 10% or greater weight loss within 15 months. Clinically significant weight loss (%) over the first 15 months was achieved with phentermine/topiramate ER (-6.3%) and liraglutide (-7.5%), but not with orlistat (-3.9%) and lorcaserin (-3.6%). Comorbid obstructive sleep apnea was negatively associated with achieving ≥5% weight loss.</p><p><strong>Conclusion: </strong>Phentermine/topiramate ER and liraglutide were found to be effective AOMs among veterans. Further work is needed to mitigate barriers to AOM initiation given the continued rise in obesity.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae042"},"PeriodicalIF":3.0,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Decreased Bone Density and Hyperlipidemia in a Taiwanese Older Adult Population.","authors":"Hui-Ming Chen, Chung-Yuan Hsu, Bo-Lin Pan, Chih-Fang Huang, Chao-Tung Chen, Hung-Yi Chuang, Chih-Hung Lee","doi":"10.1210/jendso/bvae035","DOIUrl":"https://doi.org/10.1210/jendso/bvae035","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to determine if a combination of 2 abnormal lipid profiles revealed a stronger association with low bone mass than a single blood lipid abnormality alone.</p><p><strong>Methods: </strong>This study enrolled 1373 participants who had received a dual-energy x-ray absorptiometry scan from January 2016 to December 2016 in a medical center in southern Taiwan. Logistic regression was used to examine association between lipid profiles and osteopenia or osteoporosis after adjusting for covariates.</p><p><strong>Results: </strong>Compared to people with total cholesterol (TC) < 200 mg/dL, those with TC ≥ 240 mg/dL tended to have osteopenia or osteoporosis (OR 2.61; 95% CI, 1.44-4.71). Compared to people with low-density lipoprotein cholesterol (LDL-C) < 130 mg/dL, those with LDL-C ≥ 160 mg/dL tended to develop osteopenia or osteoporosis (OR 2.13; 95% CI, 1.21-3.74). The association of increased triglyceride and decreased bone mass was similar, although not statistically significant. Those with the combination of TG ≥ 200 mg/dL and TC ≥ 240 mg/dL had a stronger tendency to have osteopenia or osteoporosis (OR 3.51; 95% CI, 1.11-11.13) than people with only one blood lipid abnormality. Similarly, people with TG ≥ 200 mg/dL and LDL-C ≥ 160 mg/dL had a stronger tendency to have osteopenia or osteoporosis (OR 9.31; 95% CI, 1.15-75.42) than people with only one blood lipid abnormality, after adjustment for the same covariates.</p><p><strong>Conclusion: </strong>Blood levels of TC, LDL-C, and TG were associated with osteopenia or osteoporosis. Results indicate that individuals aged older than 50 years with abnormal lipid profiles should be urged to participate in a bone density survey to exclude osteopenia or osteoporosis.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae035"},"PeriodicalIF":4.1,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Chemerin Levels Correlate With Severity of Dysglycemia in Young Adult Women With Polycystic Ovary Syndrome.","authors":"Chiranjit Bose, Bidisha Mukherjee, Ananya Mukherjee, Subhasish Pramanik, Chinmay Saha, Asif Mondal, Satinath Mukhopadhyay","doi":"10.1210/jendso/bvae023","DOIUrl":"10.1210/jendso/bvae023","url":null,"abstract":"<p><strong>Context: </strong>A subset of polycystic ovary syndrome (PCOS) individuals also have type 2 diabetes (T2D); an unmet need to identify this subgroup exists.</p><p><strong>Objective: </strong>We looked at the potential role of serum chemerin, a proinflammatory adipokine, in identifying dysglycemic PCOS.</p><p><strong>Methods: </strong>A total of 93 PCOS and 33 healthy controls were classified, based on fasting and 2-hour plasma glucose levels (2hPGPG) and glycated hemoglobin A_1c (HbA_1c) (%) into normoglycemic (n = 34), dysglycemic (n = 33), and T2D (n = 26). Serum chemerin were measured by enzyme-linked immunosorbent assay. Homeostatic model 2 assessment of insulin resistance (HOMA-2IR) and homeostatic model 2 assessment of β-cell function (HOMA-2β) were computed using serum C-peptide.</p><p><strong>Results: </strong>Metabolic syndrome was present in 9.7% (National Cholesterol Education Program) of PCOS. Waist circumference, body fat (%), 2hPGPG, and HbA_1c levels were significantly higher in T2D group. Serum triglycerides/high-density lipoprotein cholesterol (TGs/HDL-c) ratio was increased in PCOS individuals with T2D; no significant changes in total cholesterol and LDL-c levels were seen. Serum chemerin levels were significantly higher (<i>P</i> < .001) in the PCOS group. Total body fat (%), 2hPGPG, HbA_1c, and TG/HDL-c ratio correlated positively with chemerin levels. Serum chemerin levels correlated positively with HOMA2IR and negatively with HOMA-2β. On receiver operating characteristic curve analysis, a serum chemerin cutoff level of greater than 309.3 ng/mL differentiated PCOS individuals with dysglycemia from those without (sensitivity 85.71%, specificity 89.47%). The Cohen kappa test revealed a substantial agreement (<i>P</i> < .001) between chemerin cutoff and 2hPGPG levels greater than 200 mg/dL. The present study is arguably the first ever to define a serum chemerin cutoff to distinguish PCOS individuals with T2D from those without.</p><p><strong>Conclusion: </strong>Elevated serum chemerin levels reliably identify PCOS individuals with dysglycemia. Further, longitudinal studies with larger samples are required to confirm this association.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 4","pages":"bvae023"},"PeriodicalIF":4.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moon-like Facies by Glucocorticoid Is Associated With the Development of Diabetes and Body Image Disturbance.","authors":"Takahiro Tsutsumi, Daiki Nakagomi, Kei Kobayashi, Shunichiro Hanai, Yoshiaki Kobayashi, Ryosuke Ito, Toshihisa Ishii, Hideyuki Okuma, Hiroyuki Uchinuma, Masashi Ichijo, Kyoichiro Tsuchiya","doi":"10.1210/jendso/bvae036","DOIUrl":"10.1210/jendso/bvae036","url":null,"abstract":"<p><strong>Context: </strong>Moon-like facies (MLF) are a typical side effect of glucocorticoid (GC) therapy; however, its predisposing factors, relationship with GC-induced complications, and effects on body image are not well understood.</p><p><strong>Objective: </strong>This study aimed to determine the predisposing factors for MLF during GC therapy; its association with GC-induced diabetes, hypertension, and dyslipidemia; and its effects on body image.</p><p><strong>Methods: </strong>This prospective observational study spanned 24 weeks and targeted patients who received GC therapy at the University of Yamanashi Hospital from June 2020 to August 2022. The MLF was defined based on the following 3 factors: (1) an increase in facial measurement lengths, (2) subjective facial changes by patients' self-assessment using a visual analog scale; (3) objective and qualitative facial changes assessed by physicians. We examined the predisposing factors for MLF and the association of MLF with GC-induced diabetes, hypertension, dyslipidemia, and body image.</p><p><strong>Results: </strong>The cumulative incidence rate of MLF at 24 weeks was 37.6%. Predisposing factors for MLF were an initial oral prednisolone dosage of ≥ 30 mg/day [odds ratio (OR) 63.91, 95% confidence interval (CI) 5.82-701.81] and female (OR 6.66, 95% CI 1.35-32.79). MLF showed a significant association with the onset of GC-induced diabetes (OR 6.58, 95% CI 1.25-34.74). MLF was also an independent factor contributing to body image disturbance (β = -18.94, <i>P</i> = .01).</p><p><strong>Conclusion: </strong>MLF contributes to body image disturbance and is associated with the development of GC-induced diabetes; therefore, it is clinically important as a physical manifestation of GC therapy.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae036"},"PeriodicalIF":4.1,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Activity, Sedentary Behavior, and Pancreatic Cancer Risk: A Mendelian Randomization Study.","authors":"Manuel Gentiluomo, Suzanne C Dixon-Suen, Riccardo Farinella, Giulia Peduzzi, Federico Canzian, Roger L Milne, Brigid M Lynch, Daniele Campa","doi":"10.1210/jendso/bvae017","DOIUrl":"10.1210/jendso/bvae017","url":null,"abstract":"<p><p>Pancreatic cancer is currently the seventh leading cause of cancer death worldwide. Understanding whether modifiable factors increase or decrease the risk of this disease is central to facilitating primary prevention. Several epidemiological studies have described the benefits of physical activity, and the risks associated with sedentary behavior, in relation to cancer. This study aimed to assess evidence of causal effects of physical activity and sedentary behavior on pancreatic cancer risk. We conducted a two-sample Mendelian randomization study using publicly available data for genetic variants associated with physical activity and sedentary behavior traits and genetic data from the Pancreatic Cancer Cohort Consortium (PanScan), the Pancreatic Cancer Case-Control Consortium (PanC4), and the FinnGen study for a total of 10 018 pancreatic cancer cases and 266 638 controls. We also investigated the role of body mass index (BMI) as a possible mediator between physical activity and sedentary traits and risk of developing pancreatic cancer. We found evidence of a causal association between genetically determined hours spent watching television (hours per day) and increased risk of pancreatic cancer for each hour increment (PanScan-PanC4 odds ratio = 1.52, 95% confidence interval 1.17-1.98, <i>P</i> = .002). Additionally, mediation analysis showed that genetically determined television-watching time was strongly associated with BMI, and the estimated proportion of the effect of television-watching time on pancreatic cancer risk mediated by BMI was 54%. This study reports the first Mendelian randomization-based evidence of a causal association between a measure of sedentary behavior (television-watching time) and risk of pancreatic cancer and that this is strongly mediated by BMI. <b>Summary:</b> Pancreatic cancer is a deadly disease that is predicted to become the second leading cause of cancer-related deaths by 2030. Physical activity and sedentary behaviors have been linked to cancer risk and survival. However, there is limited research on their correlation with pancreatic cancer. To investigate this, we used a Mendelian randomization approach to examine the genetic predisposition to physical activity and sedentariness and their relation to pancreatic cancer risk, while excluding external confounders. Our findings revealed a causal link between the time spent watching television and an increased risk of pancreatic cancer. Additionally, we determined that over half of the effect of watching television on pancreatic risk is mediated by the individual's BMI.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 4","pages":"bvae017"},"PeriodicalIF":4.1,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Sex and Origin Influence Distribution of Driver Genes and Clinical Presentation of Paraganglioma.","authors":"Susan Richter, Nicole Bechmann","doi":"10.1210/jendso/bvae038","DOIUrl":"10.1210/jendso/bvae038","url":null,"abstract":"<p><strong>Context: </strong>Sexual and ancestral differences in driver gene prevalence have been described in many cancers but have not yet been investigated in pheochromocytoma and paraganglioma (PPGL).</p><p><strong>Objective: </strong>This study aims to assess whether sex and ancestry influence prevalence of PPGL driver genes and clinical presentation.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients with PPGL considering studies from 2010 onwards that included minimal data of type of disease, sex, mutated gene, and country of origin. Additional features were recorded when available (age, tumor location, bilateral or multifocal, somatic or germline, and metastatic disease).</p><p><strong>Results: </strong>We included 2162 patients: 877 in Europe and 757 in Asia. Males presented more often with germline pathogenic variants (PVs) in genes activating hypoxia pathways (<i>P</i> = .0006) and had more often sympathetic paragangliomas (<i>P</i> = .0005) and metastasis (<i>P</i> = .0039). On the other hand, females with PPGLs due to <i>MAX</i> PVs were diagnosed later than males (<i>P</i> = .0378) and more often developed metastasis (<i>P</i> = .0497). European but not Asian females presented more often with PPGLs due to PVs in genes related to kinase signaling (<i>P</i> = .0052), particularly <i>RET</i> and <i>TMEM127</i>. Contrary to experiences from Europe, Asian patients with PPGL due to PVs in kinase signaling genes <i>NF1</i>, <i>HRAS</i>, and <i>FGFR1</i> showed a high proportion of sympathetic tumors, while European patients almost exclusively had adrenal tumors (<i>P</i> < .005).</p><p><strong>Conclusion: </strong>Personalized management of patients with PPGL might benefit from considering sexual and ancestral differences. Further studies with better clinically aligned cohorts from various origins are required to better dissect ancestral influences on PPGL development.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae038"},"PeriodicalIF":4.1,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Ethanol Ablation Achieve Durable Control of Neck Nodal Recurrences in Adults With Stage I Papillary Thyroid Cancer?","authors":"Ian D Hay, Robert A Lee, Carl C Reading, J William Charboneau","doi":"10.1210/jendso/bvae037","DOIUrl":"https://doi.org/10.1210/jendso/bvae037","url":null,"abstract":"<p><strong>Objective: </strong>Results of ethanol ablation (EA) for controlling neck nodal metastases (NNM) in adult patients with papillary thyroid carcinoma (APTC) beyond 6 months have rarely been reported. We now describe outcome results in controlling 71 NNM in 40 node-positive stage I APTC patients followed for 66 to 269 months.</p><p><strong>Methods: </strong>All 40 patients were managed with bilateral thyroidectomy and radioiodine therapy and followed with neck ultrasound (US) for >48 months after EA. Cumulative radioiodine doses ranged from 30 to 550 mCi; pre-EA 27 patients (67%) had 36 additional neck surgeries. Cytologic diagnosis of PTC in 71 NNM selected for EA was confirmed by US-guided biopsy. EA technique and follow-up protocol were as previously described.</p><p><strong>Results: </strong>The 40 patients had 1 to 4 NNM; 67/71 NNM (94%) received 2 to 4 ethanol injections (total median volume 0.8 cc). All ablated 71 NNM shrank (mean volume reduction of 93%); nodal hypervascularity was eliminated. Thirty-eight NNM (54%) with initial volumes of 12-1404 mm³ (median 164) disappeared on neck sonography. Thirty-three hypovascular foci from ablated NNM (pre-EA volume range 31-636 mm³; median 147) were still identifiable with volume reductions of 45% to 97% observed (median 81%). There were no complications and no postprocedure hoarseness. Final results were considered to be ideal or near ideal in 55% and satisfactory in 45%. There was no evidence of tumor regrowth after EA.</p><p><strong>Conclusion: </strong>Our results demonstrate that for patients with American Joint Committee on Cancer stage I APTC, who do not wish further surgery or radioiodine, and are uncomfortable with active surveillance, EA can achieve durable control of recurrent NNM.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae037"},"PeriodicalIF":4.1,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}